Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape

Trends in Immunology

Volumn 38, Issue 8, 2017, Pages 577-593

  Garg, Abhishek D ^a   Coulie, Pierre G ^b   Van den Eynde, Benoit J ^c   Agostinis, Patrizia ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; IMMUNE CHECKPOINT INHIBITOR; INTERFERON; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG; CANCER VACCINE; TUMOR ANTIGEN;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; NEXT GENERATION SEQUENCING; NONHUMAN; REVIEW; VACCINATION; ADJUVANT CHEMOTHERAPY; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASM; TRENDS;

ANTIGENS, NEOPLASM; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 85020379791     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2017.05.006     Document Type: Review

References (98)

1. Sabado, R.L., et al. Dendritic cell-based immunotherapy. Cell Res. 27 (2016), 74–95.
2. Sancho, D., et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458 (2009), 899–903.
3. Dudek, A.M., et al. Immature, Semi-mature, and fully mature dendritic cells: toward a dc-cancer cells interface that augments anticancer immunity. Front. Immunol., 4, 2013, 438.
4. Mempel, T.R., et al. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427 (2004), 154–159.
5. + T cell-dendritic cell interaction kinetics and memory fate decisions. Immunity 39 (2013), 496–507.
6. Diamond, M.S., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208 (2011), 1989–2003.
7. Bol, K.F., et al. Dendritic cell-based immunotherapy: state of the art and beyond. Clin. Cancer Res. 22 (2016), 1897–1906.
8. Lutz, M.B., Schuler, G., Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol. 23 (2002), 445–449.
9. Yang, D.H., et al. The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk. Res. 33 (2009), 665–670.
10. Kersten, K., et al. Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy. Front. Immunol., 6, 2015, 516.
11. Cohn, L., Delamarre, L., Dendritic cell-targeted vaccines. Front. Immunol., 5, 2014, 255.
12. Anguille, S., et al. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 15 (2014), e257–e267.
13. Benci, J.L., et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell, 167, 2016 1540–1554.e12.
14. Garg, A.D., et al. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget 6 (2015), 26841–26860.
15. Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68.
16. Hodi, F.S., et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34 (2016), 1510–1517.
17. Restifo, N.P., et al. Acquired resistance to immunotherapy and future challenges. Nat. Rev. Cancer 16 (2016), 121–126.
18. Dillman, R.O., Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?. Hum. Vaccin. Immunother. 13 (2017), 528–532.
19. Koyama, S., et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun., 7, 2016, 10501.
20. Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
21. Braun, D.A., et al. Genomic approaches to understanding response and resistance to immunotherapy. Clin. Cancer Res. 22 (2016), 5642–5650.
22. Gao, J., et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167 (2016), 397–404 e399.
23. Kong, Y.-M., Flynn, J.C., Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front. Immunol., 5, 2014, 206.
24. Romero, P., et al. The Human Vaccines Project: a roadmap for cancer vaccine development. Sci. Transl. Med., 8, 2016, 334ps339.
25. van der Burg, S.H., et al. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat. Rev. Cancer 16 (2016), 219–233.
26. Ahmed, M.S., Bae, Y.S., Dendritic cell-based therapeutic cancer vaccines: past, present and future. Clin. Exp. Vaccine Res 3 (2014), 113–116.
27. Anguille, S., et al. Dendritic cells as pharmacological tools for cancer immunotherapy. Pharmacol. Rev. 67 (2015), 731–753.
28. Butterfield, L.H., Dendritic cells in cancer immunotherapy clinical trials: are we making progress?. Front. Immunol., 4, 2013, 454.
29. Lim, D.S., et al. DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors. Cancer Immunol. Immunother. 56 (2007), 1817–1829.
30. Chiang, C.L., et al. Whole tumor antigen vaccines. Semin. Immunol. 22 (2010), 132–143.
31. Bloy, N., et al. Trial watch: dendritic cell-based anticancer therapy. Oncoimmunology, 3, 2014, e963424.
32. Galluzzi, L., et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 1 (2012), 1111–1134.
33. Wilgenhof, S., et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J. Clin. Oncol. 34 (2016), 1330–1338.
34. Neller, M.A., et al. Antigens for cancer immunotherapy. Semin. Immunol. 20 (2008), 286–295.
35. Draube, A., et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One, 6, 2011, e18801.
36. Lion, E., et al. NK cells: key to success of DC-based cancer vaccines?. Oncologist 17 (2012), 1256–1270.
37. Kantoff, P.W., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363 (2010), 411–422.
38. Tel, J., et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 73 (2013), 1063–1075.
39. Schreibelt, G., et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin. Cancer Res. 22 (2016), 2155–2166.
40. Schreibelt, G., et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. 59 (2010), 1573–1582.
41. Cella, M., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5 (1999), 919–923.
42. + dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer. J. Immunother. 38 (2015), 71–76.
43. Garg, A.D., et al. Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing. Cell Death Differ. 24 (2017), 832–843.
44. Kroemer, G., et al. Immunogenic cell death in cancer therapy. Ann. Rev. Immunol 31 (2013), 51–72.
45. Garg, A.D., et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front. Immunol., 6, 2015, 588.
46. Garg, A.D., et al. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci. Transl. Med., 8, 2016, 328ra327.
47. Aaes, T.L., et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep. 15 (2016), 274–287.
48. Koks, C.A., et al. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int. J. Cancer 136 (2015), E313–E325.
49. Casares, N., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202 (2005), 1691–1701.
50. Zappasodi, R., et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res. 70 (2010), 9062–9072.
51. Garg, A.D., et al. Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ. 23 (2016), 938–951.
52. Overwijk, W.W., et al. Mining the mutanome: developing highly personalized immunotherapies based on mutational analysis of tumors. J. Immunother. Cancer, 1, 2013, 11.
53. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
54. Carreno, B.M., et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348 (2015), 803–808.
55. Kaiser, J., Personalized tumor vaccines keep cancer in check. Science, 356, 2017 122–122.
56. Joseph, C.G., et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343 (2014), 152–157.
57. Kranz, L.M., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534 (2016), 396–401.
58. Brahmer, J., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
59. Garon, E.B., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 2018–2028.
60. Borghaei, H., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 1627–1639.
61. Robert, C., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372 (2015), 2521–2532.
62. Robert, C., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372 (2015), 320–330.
63. Weber, J.S., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16 (2015), 375–384.
64. Motzer, R.J., et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J. Clin. Oncol. 33 (2015), 1430–1437.
65. Motzer, R.J., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373 (2015), 1803–1813.
66. Hamanishi, J., et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33 (2015), 4015–4022.
67. Kourie, H.R., et al. Learning from the “tsunami” of immune checkpoint inhibitors in 2015. Crit. Rev. Oncol. Hematol. 101 (2016), 213–220.
68. Brahmer, J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
69. Bustamante Alvarez, J.G., et al. Advances in immunotherapy for treatment of lung cancer. Cancer Biol. Med 12 (2015), 209–222.
70. Kyi, C., Postow, M.A., Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 588 (2014), 368–376.
71. Lynch, T.J., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30 (2012), 2046–2054.
72. Postow, M.A., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372 (2015), 2006–2017.
73. Ribas, A., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31 (2013), 616–622.
74. Yang, J.C., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30 (2007), 825–830.
75. Chabanon, R.M., et al. Mutational landscape and sensitivity to immune checkpoint blockers. Clin. Cancer Res. 22 (2016), 4309–4321.
76. Brown, S.D., et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 24 (2014), 743–750.
77. Garg, A.D., et al. Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. Oncoimmunology, 6, 2017, e1295903.
78. Polyzoidis, S., et al. Active dendritic cell immunotherapy for glioblastoma: Current status and challenges. Br. J. Neurosurg. 29 (2015), 197–205.
79. Molina, A.M., Nanus, D.M., Recent advances in the management of renal cell carcinoma. F1000Res., 5, 2016 F1000 Faculty Rev-391.
80. Grunwald, V., T-cell checkpoint inhibitors in metastatic renal cell carcinoma. Curr. Opin. Urol. 25 (2015), 411–415.
81. Garg, A.D., et al. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: a large-scale meta-analysis. Oncoimmunology, 5, 2016, e1069938.
82. Galon, J., et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39 (2013), 11–26.
83. Ciampricotti, M., et al. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat. Med. 18 (2012), 344–346.
84. Textor, A., et al. Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J. Exp. Med. 213 (2016), 2333–2348.
85. Laoui, D., et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat. Commun., 7, 2016, 13720.
86. Shore, N.D., Advances in the understanding of cancer immunotherapy. BJU Int. 116 (2015), 321–329.
87. Dewitte, H., et al. Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment. Nano Today 9 (2014), 743–758.
88. Melero, I., et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11 (2014), 509–524.
89. Germeau, C., et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201 (2005), 241–248.
90. Coulie, P.G., et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14 (2014), 135–146.
91. Constantino, J., et al. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. Transl. Res. 168 (2016), 74–95.
92. Lennerz, V., et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 16013–16018.
93. Jonuleit, H., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27 (1997), 3135–3142.
94. + T cells is crucial to inhibit the growth of mucosal tumors. Sci. Transl. Med., 5, 2013, 172ra120.
95. Celli, S., et al. How many dendritic cells are required to initiate a T-cell response?. Blood 120 (2012), 3945–3948.
96. Inoges, S., et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl. Cancer Inst. 98 (2006), 1292–1301.
97. Eggermont, A.M., Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin. Cancer Res. 15 (2009), 6745–6747.
98. Zitvogel, L., et al. Microbiome and anticancer immunosurveillance. Cell 165 (2016), 276–287.